Tagrisso shows benefit in NSCLC patients with CNS metastases

7th June 2017 Uncategorised 0

AstraZeneca has presented new data showing that Tagrisso also extends progression-free survival for non-small cell lung cancer (NSCLC) patients who have central nervous system (CNS) metastases.

More: Tagrisso shows benefit in NSCLC patients with CNS metastases
Source: News